Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label NOE-105 study in Tourette syndrome
ACTRN12621000319875Phase 2Completed
- Sponsor
- Noema Pharma
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gemlapodect in Tourette syndrome (TS), sponsored by Noema Pharma. Primary endpoint: Tourette Syndrome Clinical Global Impression of Change responder rate. Started Jun 2021; status: completed.
02
Drugs
gemlapodect
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on ACTRN12621000319875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000319875.